Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 666,705
  • Shares Outstanding, K 50,623
  • Annual Sales, $ 83,330 K
  • Annual Income, $ -227,100 K
  • EBIT $ -155 M
  • EBITDA $ -143 M
  • 60-Month Beta 1.14
  • Price/Sales 8.57
  • Price/Cash Flow N/A
  • Price/Book 4.41

Options Overview Details

View History
  • Implied Volatility 172.91% (+76.22%)
  • Historical Volatility 61.32%
  • IV Percentile 75%
  • IV Rank 27.23%
  • IV High 483.38% on 09/23/25
  • IV Low 56.71% on 01/17/25
  • Expected Move (DTE 28) 2.47 (18.25%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 35
  • Volume Avg (30-Day) 120
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 5,303
  • Open Int (30-Day) 4,449
  • Expected Range 11.05 to 15.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.01
  • Number of Estimates 6
  • High Estimate 0.14
  • Low Estimate -1.65
  • Prior Year -1.01
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.76 +25.56%
on 11/21/25
14.93 -9.53%
on 12/15/25
+2.26 (+20.09%)
since 11/18/25
3-Month
8.68 +55.58%
on 09/22/25
14.93 -9.53%
on 12/15/25
+4.15 (+44.34%)
since 09/18/25
52-Week
5.03 +168.32%
on 04/09/25
14.93 -9.53%
on 12/15/25
+5.74 (+73.87%)
since 12/18/24

Most Recent Stories

More News
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44 th Annual J.P. Morgan Healthcare Conference.

RGNX : 13.51 (+2.58%)
REGENXBIO to Participate in Upcoming Investor Conference

ROCKVILLE, Md. , Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference:

RGNX : 13.51 (+2.58%)
Regenxbio: Q3 Earnings Snapshot

Regenxbio: Q3 Earnings Snapshot

RGNX : 13.51 (+2.58%)
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

ROCKVILLE, Md. , Nov. 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2025.

RGNX : 13.51 (+2.58%)
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

ROCKVILLE, Md. , Oct. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the AFFINITY DUCHENNE ® pivotal trial of RGX-202, an investigational...

RGNX : 13.51 (+2.58%)
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

ROCKVILLE, Md. , Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m. ET to discuss its financial...

RGNX : 13.51 (+2.58%)
REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. , Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

RGNX : 13.51 (+2.58%)
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

ROCKVILLE, Md. , Oct. 9, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE ® trial evaluating suprachoroidal delivery...

RGNX : 13.51 (+2.58%)
Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), RegenXBio (RGNX) and Vera Therapeutics (VERA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report), RegenXBio (RGNX – Research Report) and Vera Therapeutics...

VERA : 47.69 (-1.73%)
AVXL : 3.89 (-0.77%)
RGNX : 13.51 (+2.58%)
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

ROCKVILLE, Md. , Oct. 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the ATMOSPHERE ® and ASCENT ® pivotal studies evaluating surabgene...

RGNX : 13.51 (+2.58%)

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 15.00
2nd Resistance Point 14.58
1st Resistance Point 14.04
Last Price 13.51
1st Support Level 13.09
2nd Support Level 12.67
3rd Support Level 12.13

See More

52-Week High 14.93
Last Price 13.51
Fibonacci 61.8% 11.15
Fibonacci 50% 9.98
Fibonacci 38.2% 8.82
52-Week Low 5.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar